Incidence rate and factors associated with the development of secondary cancers after radioiodine therapy in differentiated thyroid cancer: a multicenter retrospective study

Abstract Purpose The objective of this study was to estimate the incidence of secondary cancers and the factors associated with their development among patients who underwent radioiodine therapy (RIT) with differentiated thyroid cancer. Methods We retrospectively collected medical records for patients who underwent first RIT between January 1, 2000 and December 31, 2005 from seven tertiary hospitals in South Korea after total thyroidectomy for differentiated thyroid cancer. Cancer incidence and calculated standardized rate ratio was compared with Korean cancer incidence data. The association between the development of secondary cancers and various parameters was analyzed by Cox-proportional hazard regression. Results A total of 3106 patients were included in this study. Mean age at the time of diagnosis of thyroid cancer was 45.7 ± 13.3 years old, and 2669 (85.9%) patients were female. The follow-up period was 11.9 ± 4.6 (range, 1.2–19.6) years. A total of 183 secondary cancers (5.6%), which included 162 solid and 21 hematologic cancers occurred in 173 patients. There was no significant difference between solid cancer incidence in our study population who underwent RIT and the overall Korean population, but the incidence of hematologic cancers and total cancer in our study was significantly higher compared with that of the Korean population. A multivariate analysis identified independent prognostic factors for the development of secondary cancer including age at 1st RIT, male, and total cumulative dose over 200 mCi. Conclusion We need to assess the risk benefit for patients who receive over 200 mCi of a total cumulative dose.

Download Full-text

Factors Associated with Clinical Outcomes of Differentiated Thyroid Cancer Following Radioiodine Therapy in Tanzania

Cancer Research Journal ◽

10.11648/j.crj.20190703.11 ◽

2019 ◽

Vol 7 (3) ◽

pp. 73

Author(s):

Lulu Lunogelo Sakafu ◽

Teddy Frank Mselle ◽

Julius David Mwaiselage ◽

Khamza Kibwana Maunda ◽

Katherine Van Loon ◽

...

Keyword(s):

Thyroid Cancer ◽

Clinical Outcomes ◽

Differentiated Thyroid Cancer ◽

Radioiodine Therapy ◽

Factors Associated

Download Full-text

Predictive factors determining incomplete response to radioiodine therapy in patients with differentiated thyroid cancer

The Quarterly Journal of Nuclear Medicine and Molecular Imaging ◽

10.23736/s1824-4785.18.03026-1 ◽

2020 ◽

Vol 64 (1) ◽

Author(s):

Ewelina Szczepanek-Parulska ◽

Magdalena Wojewoda-Korbelak ◽

Martyna Borowczyk ◽

Malgorzata Kaluzna ◽

Barbara Brominska ◽

...

Keyword(s):

Thyroid Cancer ◽

Predictive Factors ◽

Differentiated Thyroid Cancer ◽

Radioiodine Therapy ◽

Incomplete Response

Download Full-text

Radioiodine therapy reduces the frequency of circulating tumour cells in patients with differentiated thyroid cancer

Clinical Endocrinology ◽

10.1111/cen.14419 ◽

2021 ◽

Author(s):

Mathias Schmidt ◽

Christina Antke ◽

Katalin Mattes‐György ◽

Hubertus Hautzel ◽

Stephanie Allelein ◽

...

Keyword(s):

Thyroid Cancer ◽

Differentiated Thyroid Cancer ◽

Radioiodine Therapy ◽

Tumour Cells ◽

Circulating Tumour Cells

Download Full-text

Health-Related Quality of Life in Asian Differentiated Thyroid Cancer Survivors

Cancer Control ◽

10.1177/10732748211029726 ◽

2021 ◽

Vol 28 ◽

pp. 107327482110297

Author(s):

Wing-Lok Chan ◽

Horace Cheuk-Wai Choi ◽

Brian Lang ◽

Kai-Pun Wong ◽

Kwok-Keung Yuen ◽

...

Keyword(s):

Quality Of Life ◽

Thyroid Cancer ◽

Cancer Survivors ◽

Differentiated Thyroid Cancer ◽

Summary Score ◽

Health Related Quality ◽

Factors Associated ◽

Related Quality ◽

Health Related

Background: Health-related quality of life (HRQoL) is important for differentiated thyroid cancer survivors, but data for Asian survivors is lacking. This study aimed to have an overview of, and identify any disease-or treatment-related factors associated with, HRQoL in Asian differentiated thyroid cancer survivors. Patients and Methods: Thyroid cancer survivors were recruited from the thyroid clinics at Queen Mary Hospital, Hong Kong from February 2016 to December 2016. All adult differentiated thyroid cancer patients with stable disease more than or equal to 1 year received a survey on HRQoL using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and Thyroid cancer specific quality of life (THYCA-QoL) questionnaire. Clinical information was collected retrospectively from the computerized clinical management system. To identify factors associated with poor HRQoL, univariable and stepwise multivariable regression analysis were performed. Results: A total of 613 survivors completed the questionnaires (response rate: 82.1%; female: 80.1%; median survivorship: 7.4 years (range: 1.0-48.2 years)). The QLQ-C30 summary score mean was 84.4 (standard deviation (SD): 12.7) while the THYCA-QoL summary score mean was 39.9 (SD: 9.7). The 2 highest symptom subscales were fatigue (mean: 26.4, SD: 20.6) and insomnia (mean: 26.2, SD: 27.6). Factors associated with worse HRQoL included serum thyrotropin (TSH) greater than 1.0 mIU/L, unemployment, and concomitant psychiatric disorders. Concomitant psychiatric illness (n = 40/613, 6.5%) also showed significant association with most of the symptom and functional subscales. Conclusions: Fatigue and insomnia were the 2 most common symptoms experienced by our differentiated thyroid cancer survivors. Long-term survivorship care with monitoring serum TSH level, supporting return-to-work and screening for concomitant psychiatric disorders should be offered.

Download Full-text